



# somatrogon 24mg and 60mg solution for injection in pre-filled pen (Ngenla®)

Pfizer Ltd

08 July 2022

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and, following review by the SMC executive, advises NHS Boards and Area Drug and Therapeutics Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows:

**ADVICE:** following an abbreviated submission

**somatrogon (Ngenla®)** is accepted for use within NHSScotland.

**Indication under review:** for the treatment of children and adolescents from 3 years of age with growth disturbance due to insufficient secretion of growth hormone.

Somatrogon offers an additional treatment choice in the therapeutic class of recombinant human growth hormones for this indication.

## Advice context:

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

*This assessment is based on data submitted by the applicant company up to and including 01 April 2022.*

**Chairman**  
**Scottish Medicines Consortium**